Travere Therapeutics, Inc.(TVTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TVTX Travere Therapeutics, Inc.

盘前交易 01-13 09:17:51 EST

34.10

-0.48

-1.39%

盘前22.80

-11.30-33.14%

09:17 EST

最高34.56	最低32.25	成交量419.25万
今开34.27	昨收34.58	日振幅6.69%
总市值30.51亿	流通市值27.04亿	总股本8,947万
成交额1.40亿	换手率5.29%	流通股本7,929万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TVTX","market":"US","secType":"STK","nameCN":"Travere Therapeutics, Inc.","latestPrice":34.1,"timestamp":1768251600000,"preClose":34.58,"halted":0,"volume":4192470,"hourTrading":{"tag":"盘前","latestPrice":22.7982,"preClose":34.1,"latestTime":"09:17 EST","volume":433871,"amount":10337899.418617,"timestamp":1768313870936},"delay":0,"floatShares":79285667,"shares":89472327,"eps":-1.015189,"marketStatus":"盘前交易","change":-0.48,"latestTime":"01-13 09:17:51 EST","open":34.265,"high":34.562,"low":32.25,"amount":139750017.37272,"amplitude":0.066859,"askPrice":22.9,"askSize":500,"bidPrice":22.74,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-1.015189,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768314600000},"marketStatusCode":1,"adr":0,"listingDate":1389330000000,"exchange":"NASDAQ","adjPreClose":34.1,"preHourTrading":{"tag":"盘前","latestPrice":22.7982,"preClose":34.1,"latestTime":"09:17 EST","volume":433871,"amount":10337899.418617,"timestamp":1768313870936},"postHourTrading":{"tag":"盘后","latestPrice":22.12,"preClose":34.1,"latestTime":"19:59 EST","volume":1232888,"amount":30655903.7377,"timestamp":1768265999976},"volumeRatio":1.621579660857847,"impliedVol":1.75,"impliedVolPercentile":1},"requestUrl":"/m/hq/s/TVTX","defaultTab":"news","newsList":[{"id":"1153311018","title":"Travere Therapeutics公布关于Filspari在FSGS的第三阶段Duplex研究的最新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1153311018","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153311018?lang=zh_cn&edition=full","pubTime":"2025-11-07 00:01","pubTimestamp":1762444873,"startTime":"0","endTime":"0","summary":"Travere Therapeutics公布关于Filspari在FSGS的第三阶段Duplex研究的最新数据，数据将在2025年美国肾脏病学会（ASN）肾脏周期间发布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVTX"],"gpt_icon":0},{"id":"2567190639","title":"生物科技股集体重挫！报道称特朗普政府将儿童死亡甩锅新冠疫苗接种","url":"https://stock-news.laohu8.com/highlight/detail?id=2567190639","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567190639?lang=zh_cn&edition=full","pubTime":"2025-09-13 06:38","pubTimestamp":1757716705,"startTime":"0","endTime":"0","summary":"研发新冠疫苗的BioNTech盘中跌超10%、莫德纳跌超7%、Novavax跌超4%。投资者担心，如果特朗普政府进一步收紧疫苗接种政策，可能对疫苗制造商的业务造成重大冲击，特别是对莫德纳这类高度依赖新冠疫苗收入的公司。更新中","market":"us","thumbnail":"https://static.tigerbbs.com/632b4e916ff966270173f4303843021f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/632b4e916ff966270173f4303843021f"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3755508","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"ae8bc75ba4d1918dcafc0476d86c6d53","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3755508","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"生物科技股集体重挫！报道称特朗普政府将儿童死亡甩锅新冠疫苗接种","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["ABUS","STRO","SRPT","MRK","PGEN","BMY","PFE","NVS","TARS","AZN","KALV","MRNA","NVAX","TRVI","TVTX","PSNL","ARCT","BNTX","BK4009"],"gpt_icon":1},{"id":"1171090232","title":"FDA批准跳过咨询委员会审查，Travere Therapeutics股价盘前大涨17.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171090232","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171090232?lang=zh_cn&edition=full","pubTime":"2025-09-10 20:26","pubTimestamp":1757507176,"startTime":"0","endTime":"0","summary":"Travere Therapeutics股价在盘前交易中大幅上涨17.8%，此前美国食品药品监督管理局(FDA)批准该公司的肾脏疾病治疗药物可以跳过咨询委员会的审查程序。这一决定为该公司的药物审批流程提供了便利，投资者对此消息反应积极，推动股价显著上扬。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVTX","BK4139"],"gpt_icon":0},{"id":"1140041580","title":"Travere Therapeutics就Filspari®（Sparsentan）治疗FSGS的FDA咨询委员会会议提供最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1140041580","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140041580?lang=zh_cn&edition=full","pubTime":"2025-09-10 19:03","pubTimestamp":1757502183,"startTime":"0","endTime":"0","summary":"Travere Therapeutics公司发布了关于其药物Filspari®（Sparsentan）用于治疗FSGS的FDA咨询委员会会议的最新情况说明。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVTX"],"gpt_icon":0},{"id":"1120039685","title":"Travere Therapeutics宣布美国FDA批准修改Filspari®（sparsentan）治疗IgA肾病的风险评估与缓解策略","url":"https://stock-news.laohu8.com/highlight/detail?id=1120039685","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120039685?lang=zh_cn&edition=full","pubTime":"2025-08-28 05:10","pubTimestamp":1756329026,"startTime":"0","endTime":"0","summary":"Travere Therapeutics宣布美国FDA批准修改Filspari®（sparsentan）治疗IgA肾病的风险评估与缓解策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVTX","BK4139"],"gpt_icon":0},{"id":"1153688427","title":"异动解读 | 财报不佳，Travere Therapeutics盘中大跌5.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153688427","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153688427?lang=zh_cn&edition=full","pubTime":"2025-08-07 22:01","pubTimestamp":1754575288,"startTime":"0","endTime":"0","summary":"周四盘中，Travere Therapeutics股价大幅下跌5.51%，引发投资者关注。消息面上，Travere Therapeutics发布了令人失望的第二季度财报。数据显示，公司第二季度每股亏损0.14美元，营业收入为负1265万美元。同期，公司营业费用高达1.27099亿美元，净亏损1275.5万美元。分析人士认为，Travere Therapeutics的财务状况不佳可能是导致股价下跌的主要原因。高额的营业费用和持续的亏损状态引发了投资者对公司未来盈利能力的担忧。尽管产品销售额表现尚可，但未能抵消巨额支出带来的负面影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TVTX"],"gpt_icon":0},{"id":"1104541455","title":"异动解读 | Travere Therapeutics盘中大跌5.51%，二季度业绩不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1104541455","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104541455?lang=zh_cn&edition=full","pubTime":"2025-08-07 22:01","pubTimestamp":1754575288,"startTime":"0","endTime":"0","summary":"周四盘中，Travere Therapeutics股价出现大幅下跌，跌幅高达5.51%，引发投资者关注。根据Travere Therapeutics公布的财报显示，公司第二季度每股收益为-0.14美元，营业收入为-1265万美元。分析人士指出，Travere Therapeutics的股价下跌可能主要源于其财务业绩不及市场预期。尽管公司报告了产品销售额接近9500万美元，但总体营业收入为负值，显示公司可能面临着严重的成本压力。这些因素综合导致了投资者信心下降，进而推动了股价的大幅下跌。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TVTX"],"gpt_icon":0},{"id":"1180202736","title":"异动解读 | Travere Therapeutics盘后大涨5.86%，季度亏损远低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1180202736","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180202736?lang=zh_cn&edition=full","pubTime":"2025-08-07 06:12","pubTimestamp":1754518357,"startTime":"0","endTime":"0","summary":"Travere Therapeutics, Inc.股价在盘后交易中大涨5.86%，引起投资者广泛关注。这一显著涨幅主要源于公司发布的最新季度财报优于市场预期。根据公司公布的财报，截至6月30日的季度调整后每股亏损为14美分，远低于分析师平均预期的30美分亏损。值得注意的是，尽管Travere Therapeutics今年以来股价下跌了4.2%，但分析师对公司前景保持乐观。这些积极的分析师评价可能进一步提振了投资者信心，推动股价上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TVTX"],"gpt_icon":1},{"id":"2514868388","title":"小摩：维持Travere Therapeutics(TVTX.US)评级，由增持调整至增持评级, 目标价由42.00美元调整至44.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514868388","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514868388?lang=zh_cn&edition=full","pubTime":"2025-02-27 00:58","pubTimestamp":1740589098,"startTime":"0","endTime":"0","summary":"小摩：维持Travere Therapeutics(TVTX.US)评级，由增持调整至增持评级, 目标价由42.00美元调整至44.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27005848413817.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","TVTX"],"gpt_icon":0},{"id":"1190867740","title":"异动解读 | Travere Therapeutics股价盘中大涨5.91% 投资者看好罕见肾病新药前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1190867740","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190867740?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:31","pubTimestamp":1740583910,"startTime":"0","endTime":"0","summary":"生物制药公司Travere Therapeutics股价当日盘中大涨5.91%,投资者对公司研发的罕见肾病新药sparsentan的前景看好。Travere Therapeutics专注于为患有罕见肾脏、肝脏和代谢疾病的人研发新药。其在研新药sparsentan是治疗局灶节段性肾小球硬化症和IgA肾病的后期候选药物,如果顺利获批上市,将为公司带来重大利好。虽然公司目前净利润为负,但营收和毛利较高,处于盈利前投入期正常状态。投资者看好sparsentan获批并推动公司业绩大幅增长的预期,推动了当日股价大涨超5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Travere Therapeutics股价盘中大涨5.91% 投资者看好罕见肾病新药前景","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TVTX"],"gpt_icon":0},{"id":"2514854832","title":"Travere Therapeutics, Inc.盘中异动 股价大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514854832","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514854832?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:24","pubTimestamp":1740583442,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日23时24分，Travere Therapeutics, Inc.股票出现异动，股价快速拉升5.04%。Travere Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.03%。其相关个股中，Enveric Biosciences, Inc.、Athira Pharma, Inc.、Humacyte Inc C/Wts 27/08/2026 涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为5090.48%、184.17%、177.50%，振幅较大的相关个股有Enveric Biosciences, Inc.、Humacyte Inc C/Wts 27/08/2026 、Organovo Holdings, Inc.，振幅分别为161.02%、39.47%、33.94%。Travere Therapeutics, Inc.公司简介：Travere Therapeutics Inc 是一家生物制药公司，专注于为患有罕见肾脏、肝脏和代谢疾病的人识别、开发和提供改变生命的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226232403a2550337&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226232403a2550337&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TVTX","BK4139"],"gpt_icon":0},{"id":"2514677689","title":"花旗：维持Travere Therapeutics(TVTX.US)评级，由买入调整至买入评级, 目标价由31.00美元调整至35.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514677689","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514677689?lang=zh_cn&edition=full","pubTime":"2025-02-25 00:25","pubTimestamp":1740414342,"startTime":"0","endTime":"0","summary":"花旗：维持Travere Therapeutics(TVTX.US)评级，由买入调整至买入评级, 目标价由31.00美元调整至35.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25002548356350.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["TVTX","LENZ"],"gpt_icon":0},{"id":"2513877337","title":"Travere Therapeutics, Inc.盘中异动 早盘股价大跌5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513877337","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513877337?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:58","pubTimestamp":1740409101,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时58分，Travere Therapeutics, Inc.股票出现波动，股价大幅下挫5.09%。Travere Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.10%。其相关个股中，Pepgen Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Telix Pharmaceutic涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为148.73%、63.61%、25.10%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、41.14%。Travere Therapeutics, Inc.公司简介：Travere Therapeutics Inc 是一家生物制药公司，专注于为患有罕见肾脏、肝脏和代谢疾病的人识别、开发和提供改变生命的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225821abdb1489&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225821abdb1489&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TVTX","LENZ","BK4139"],"gpt_icon":0},{"id":"2513375644","title":"Travere Therapeutics, Inc.2024财年实现净利润-3.21亿美元，同比增加14.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513375644","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513375644?lang=zh_cn&edition=full","pubTime":"2025-02-24 00:01","pubTimestamp":1740326471,"startTime":"0","endTime":"0","summary":"2月24日，Travere Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-3.21亿美元，同比增加14.63%；其中营业收入为2.33亿美元，同比增加60.69%，每股基本收益为-4.08美元。机构评级：截至2025年2月24日，当前有14家机构对Travere Therapeutics, Inc.目标价做出预测，其中目标均价为34.21美元，其中最低目标价为22.00美元，最高目标价为47.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000141a250ce13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000141a250ce13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TVTX"],"gpt_icon":0},{"id":"2513136242","title":"坎托菲茨杰拉德公司：重申Travere Therapeutics(TVTX.US)评级，由增持调整至增持评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513136242","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513136242?lang=zh_cn&edition=full","pubTime":"2025-02-22 01:34","pubTimestamp":1740159250,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：重申Travere Therapeutics(TVTX.US)评级，由增持调整至增持评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/22013448321042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","TVTX"],"gpt_icon":0},{"id":"2513778299","title":"Travere Therapeutics, Inc.盘中异动 股价大跌9.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513778299","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513778299?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:31","pubTimestamp":1740148275,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时31分，Travere Therapeutics, Inc.股票出现波动，股价快速跳水9.92%。Travere Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.33%。其相关个股中，Osr Holdings, Inc.、Nkgen Biotech, Inc.、Acelyrin, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、蓝鸟生物较为活跃，换手率分别为69.10%、60.32%、17.96%，振幅较大的相关个股有Osr Holdings, Inc.、Gain Therapeutics, Inc.、Windtree Therapeutics, Inc.，振幅分别为11.30%、10.21%、7.29%。Travere Therapeutics, Inc.公司简介：Travere Therapeutics Inc 是一家生物制药公司，专注于为患有罕见肾脏、肝脏和代谢疾病的人识别、开发和提供改变生命的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223115abd7af4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223115abd7af4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","TVTX"],"gpt_icon":0},{"id":"1165114656","title":"Travere Therapeutics 第四季度调整后每股亏损 $-0.47 超预期，销售额 $7479万 超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1165114656","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165114656?lang=zh_cn&edition=full","pubTime":"2025-02-21 05:04","pubTimestamp":1740085466,"startTime":"0","endTime":"0","summary":"根据NASDAQ TVTX报道，Travere Therapeutics 公司报告了季度每股亏损 $-0.47，这一数据比分析师普遍预测的 $-0.56 高出 16.07%。相比去年同期每股亏损 $-0.94，有50%的上涨。相比去年同期的 $4506万，销售额增长了 65.98%。以上内容来自Benzinga Earnings专栏，原文如下：Travere $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 16.07 percent. This is a 50 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $74.79 million which beat the analyst consensus estimate of $73.34 ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","TVTX"],"gpt_icon":0},{"id":"2510370128","title":"Evercore ISI Group：维持Travere Therapeutics(TVTX.US)评级，由优于大市调整至优于大市评级, 目标价由33.00美元调整至45.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510370128","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510370128?lang=zh_cn&edition=full","pubTime":"2025-02-12 22:32","pubTimestamp":1739370757,"startTime":"0","endTime":"0","summary":"Evercore ISI Group：维持Travere Therapeutics(TVTX.US)评级，由优于大市调整至优于大市评级, 目标价由33.00美元调整至45.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/12223248121880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","TVTX","EVR"],"gpt_icon":0},{"id":"2510338744","title":"Travere Therapeutics, Inc.盘中异动 大幅上涨13.93%报24.04美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510338744","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510338744?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:31","pubTimestamp":1739284264,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时31分，Travere Therapeutics, Inc.股票出现异动，股价大幅拉升13.93%。Travere Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.92%。其相关个股中，Dominari Holdings Inc.、In8Bio, Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、In8Bio, Inc.较为活跃，换手率分别为1857.07%、501.54%、169.16%，振幅较大的相关个股有In8Bio, Inc.、Dominari Holdings Inc.、Abpro Holdings, Inc，振幅分别为11.26%、8.44%、6.12%。Travere Therapeutics, Inc.公司简介：Travere Therapeutics Inc 是一家生物制药公司，专注于为患有罕见肾脏、肝脏和代谢疾病的人识别、开发和提供改变生命的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223104a241fac6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223104a241fac6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","TVTX"],"gpt_icon":0},{"id":"2510865602","title":"Travere Therapeutics, Inc.盘中异动 早盘股价大跌5.23%报20.61美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510865602","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510865602?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:39","pubTimestamp":1739198378,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时39分，Travere Therapeutics, Inc.股票出现异动，股价急速下跌5.23%。Travere Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。其相关个股中，Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.较为活跃，换手率分别为1911.49%、1022.03%、683.97%，振幅较大的相关个股有Soligenix, Inc.、Biodexa Pharmaceuticals Plc、Ocean Biomedical, Inc.，振幅分别为103.16%、50.12%、34.46%。Travere Therapeutics, Inc.公司简介：Travere Therapeutics Inc 是一家生物制药公司，专注于为患有罕见肾脏、肝脏和代谢疾病的人识别、开发和提供改变生命的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223938abc9a743&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223938abc9a743&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","TVTX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://travere.com","stockEarnings":[{"period":"1week","weight":-0.1052},{"period":"1month","weight":-0.021},{"period":"3month","weight":0.3045},{"period":"6month","weight":1.0468},{"period":"1year","weight":0.885},{"period":"ytd","weight":-0.1076}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Travere Therapeutics, Inc.于2008年2月8日合并为Desert Gatewayinc公司，注册于俄克拉何马州。 Retrophin是一家处于发展阶段的生物制药公司，致力于严重疾病、灾难性疾病以及罕见疾病的治疗疗法的开发、收购和商业化。Retrophin在美国，正致力于开发 SyntocinonTM Nasal Spray，以帮助产后乳汁分泌, 并且可以用于治疗精神分裂症和自闭症。Syntocinon Nasal Spray目前由Novartis 和 Sigma-Tau 负责在欧洲以及其他国家销售，帮助孕妇产后乳汁分泌。此外, Retrophin正在开发RE-034, 一种合成激素类似物, 由包含在ACTH中39个氨基酸中的24个氨基酸组成，用以治疗婴儿痉挛症和肾病综合症。Retrophin 同时也致力于研发re - 024, 一种新型小分子, 用于泛酸盐神经退行性病变的潜在治疗。同时,该公司正在开发sparsentan, 原名为re - 021, 双重作用的血管紧缩素受体和内皮素受体, 用于治疗局灶节段性肾小球硬化症。Retrophin在临床开发方面也有几个额外的程序,包括re - 001，用于杜氏肌萎缩症的治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.002036},{"month":2,"riseRate":0.666667,"avgChangeRate":0.083029},{"month":3,"riseRate":0.416667,"avgChangeRate":0.015477},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.045444},{"month":5,"riseRate":0.5,"avgChangeRate":0.011933},{"month":6,"riseRate":0.583333,"avgChangeRate":0.032284},{"month":7,"riseRate":0.5,"avgChangeRate":0.010273},{"month":8,"riseRate":0.5,"avgChangeRate":0.058304},{"month":9,"riseRate":0.416667,"avgChangeRate":0.007125},{"month":10,"riseRate":0.5,"avgChangeRate":0.033214},{"month":11,"riseRate":0.583333,"avgChangeRate":0.03497},{"month":12,"riseRate":0.583333,"avgChangeRate":0.053144}],"exchange":"NASDAQ","name":"Travere Therapeutics, Inc.","nameEN":"Travere Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Travere Therapeutics, Inc.(TVTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Travere Therapeutics, Inc.(TVTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Travere Therapeutics, Inc.,TVTX,Travere Therapeutics, Inc.股票,Travere Therapeutics, Inc.股票老虎,Travere Therapeutics, Inc.股票老虎国际,Travere Therapeutics, Inc.行情,Travere Therapeutics, Inc.股票行情,Travere Therapeutics, Inc.股价,Travere Therapeutics, Inc.股市,Travere Therapeutics, Inc.股票价格,Travere Therapeutics, Inc.股票交易,Travere Therapeutics, Inc.股票购买,Travere Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Travere Therapeutics, Inc.(TVTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Travere Therapeutics, Inc.(TVTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}